Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3TH6Y)

• Drug Name: CBP-307 Drug Info
• Synonyms: CBP-307; CBP 307; CBP307; BCP20840; AKOS040748092

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 139266790
  TTD Drug ID: DM3TH6Y

Molecule-Related Drug Atlas

Drug(s) Targeting Sphingosine-1-phosphate receptor 1 (S1PR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siponimod	DM2R86O	Multiple sclerosis	8A40	Approved	[3]
Fingolimod	DM5JVAN	Multiple sclerosis	8A40	Approved	[4]
Ozanimod	DMT6AM2	Multiple sclerosis	8A40	Approved	[5]
Etrasimod	DMT0A3Y	Ulcerative colitis	DD71	Approved	[6]
Ponesimod	DMEAOYJ	Multiple sclerosis	8A40	Approved	[7]
MT-1303	DMSE9TH	Crohn disease	DD70	Phase 2	[8]
ONO-4641	DMLUM3Y	Rheumatoid arthritis	FA20	Phase 2	[9]
KRP-203	DMOW9X2	Cutaneous lupus erythematosus	EB5Z	Phase 2	[9]
VTX-002	DMZ8Z5A	Ulcerative colitis	DD71	Phase 2	[10]
Sphingosine-1-phosphate	DMJCQKA	Acne vulgaris	ED80	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT04700449) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC). U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Connect Biopharma
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [8] Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
• [9] Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
• [10] Clinical pipeline report, company report or official report of Ventyx Biosciences
• [11] Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.